SUVmax and metabolic tumor volume: surrogate image biomarkers of KRAS mutation status in colorectal cancer
Authors Lv Y, Wang X, Liang L, Wang L, Lu J
Received 1 December 2018
Accepted for publication 5 February 2019
Published 21 March 2019 Volume 2019:12 Pages 2115—2121
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 3
Editor who approved publication: Dr William Cho
Ying Lv,1,* Xin Wang,2,3,* Lerong Liang,4 Lei Wang,5 Jie Lu6
1Department of Gastroenterology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, Shandong, People’s Republic of China; 2Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, People’s Republic of China; 3Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan 250117, Shandong, People’s Republic of China; 4Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, Shandong, People’s Republic of China; 5Department of Gastrointestinal Surgery, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, Shandong, People’s Republic of China; 6Department of Neurosurgery, Shandong Province Qianfoshan Hospital of Shandong University, Jinan 250014, Shandong, People’s Republic of China
*These authors contributed equally to this work
Purpose: The objective of this study was to explore the association between KRAS mutation status and PET/CT metabolic parameters in colorectal cancer (CRC) patients.
Materials and methods: One hundred and sixty-four CRC patients were enrolled in this study and received PET/CT examination before operation, then KRAS mutation status was analyzed through pathologically confirmed CRC samples. The association between tumor clinical characteristics and PET/CT metabolic parameters, including maximum standardized uptake value (SUVmax), SUVmean, and metabolic tumor volume (MTV), and KRAS mutation status was analyzed using chi-squared tests, Mann–Whitney U tests, and logistic regression analysis.
Results: The KRAS mutation type patients exhibited high MTV and high SUVmax using a threshold of 17.8 cm3 and 8.7 respectively and the predictive accuracy was 0.772 and 0.603 respectively. High MTV (P=0.001; 95% CI: 1.119–1.296) and high SUVmax (P=0.048; 95% CI: 0.564–0.985) were independent predictors for KRAS mutation status.
Conclusion: MTV and SUVmax were associated with KRAS mutation type in CRC patients. PET/CT metabolic parameters can be used for supplementing KRAS mutation status prediction in CRC patients.
Keywords: colorectal cancer, 18F-FDG PET/CT, SUVmax, SUVmean, MTV, KRAS mutation
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]